Clinical Trial: Hypertriglyceridaemia - Cause and Effects

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational



Official Title: Hypertriglyceridaemia: Therapeutic Targets, Genetic Causes, and Associated Neuropathy

Brief Summary:

  1. At target LDL-C levels, apoB100 concentrations will be higher than recommended levels in the following populations:

    1. Tertiary centre lipid clinic patients with raised TG treated with statins.
    2. Patients with type 2 diabetes treated with statins.
    3. Patients with Chronic Kidney disease (CKD) stages 4 and 5 treated with statins.
  2. Despite achieving LDL-C and non-HDL-C targets, a significant number of statin-treated patients have residual cardiovascular risk related to raised hsCRP. The relationship between hsCRP and Lp-PLA2 (markers of inflammation) and LDL particle number measured by apoB100 is stronger than that of measured and calculated LDL and non-HDL. In statin treated patients there will be higher levels of hs-CRP and Lp-PLA2 in patients achieving LDL targets but not apo B targets.
  3. We hypothesise that non-diabetic patients with severe hypertriglyceridaemia (fasting serum triglyceride >5.5 mmol/l) have evidence of greater nerve damage compared with matched controls.
  4. LAL deficiency is underdiagnosed in patients with severe hypertriglyceridaemia, low HDL-C, hyperlipidaemias, non alcoholic fatty liver disease and idiopathic high liver enzymes.